All In Biotech

Drug Trial Radar · NCT06953960

A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)

A Phase 1/2, Open-Label, Platform Study to Evaluate Safety and Efficacy of the BCL-2 Inhibitor Surzetoclax (ABBV-453) Given as Monotherapy or in Combination With Antimyeloma Regimens in Subjects With Multiple Myeloma

Last checked: Nov 19, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 325 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

325

Planned (sponsor's estimate)

Start

Jul 23, 2025

Primary completion

Dec 2030

Study completion Dec 2030

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
May 1, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Multiple myeloma (MM) is a plasma cell disease characterized by the growth of clonal plasma cells in the bone marrow. The purpose of this study is to assess the safety and change in disease activity of surzetoclax in adult participants with relapsed/refractory (R/R) MM. Adverse events and change in disease activity will be assessed. Surzetoclax is an investigational drug being developed for the treatment of R/R MM. In Substudy 1 there will be dose escalation and dose expansion phases where participants will receive various doses (escalation) or 1 of 2 doses (expansion) of surzetoclax in combination with daratumumab + dexamethasone, to determine the best dose of surzetoclax. In Substudy 2, there will be a dose escalation phase where participants will receive various doses of surzetoclax alone. In Substudy 3 there will be dose escalation and optimization phases where participants will receive various doses (escalation) or 1 of 2 doses (optimization) of of surzetoclax and etentamig to determine the best dose of surzetoclax and etentamig. Optimization will also include etentamig received alone. Approximately 325 adult participants with R/R MM will be enrolled in the study in approximately 55 sites worldwide. In Substudy 1 escalation phase, participants will receive oral surzetoclax tablets in combination with subcutaneous (SC) daratumumab injections + oral dexamethasone tablets and in the expansion phase, will receive 1 of 2 doses oral surzetoclax tablets in combination with SC daratumumab injections + oral dexamethasone tablets or daratumumab injections + oral pomalidomide + oral dexamethasone tablets. In Substudy 2, Japanese participants will receive oral surzetoclax tablets. In Substudy 3 escalation phase, participants will receive oral surzetoclax tablets in combination with IV etentamig and in the expansion phase, will receive 1 of 2 doses of both oral surzetoclax tablets in combination with of IV etentamig, or IV etentamig alone. The total study duration is approximately 4.5 years. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution. The effect of the treatment will be frequently checked by medical assessments, blood tests, and side effects.

Conditions

  • Multiple Myeloma

Interventions

  • SurzetoclaxDrug

    Oral

  • DaratumumabDrug

    Subcutaneous (SC) Injection

  • DexamethasoneDrug

    Oral

  • PomalidomideDrug

    Oral

  • EtentamigDrug

    Intravenous Infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose-Limiting Toxicities (DLT)s of ABBV-453Time frame: Up to Approximately 45 Months
  2. Number of Participants with Adverse Events (AE)sTime frame: Up to Approximately 4.5 Years

Locations

51 sites in 12 countries. Site status is shown where the registry gives one.

  • University of Southern California /ID# 272414

    Los Angeles, California · Recruiting

  • Yale University School of Medicine /ID# 272447

    New Haven, Connecticut · Recruiting

  • Dana-Farber Cancer Institute /ID# 271846

    Boston, Massachusetts · Recruiting

  • University of Michigan Health System - Ann Arbor /ID# 271536

    Ann Arbor, Michigan · Recruiting

  • Memorial Sloan Kettering Cancer Center - New York - York Avenue /ID# 271214

    New York, New York · Recruiting

  • Atrium Health Levine Cancer Institute /ID# 271510

    Charlotte, North Carolina · Recruiting

  • University Of North Carolina Health Care - Hillsborough Campus /ID# 272454

    Hillsborough, North Carolina · Recruiting

  • Atrium Health Wake Forest Baptist Medical Center /ID# 271294

    Winston-Salem, North Carolina · Recruiting

  • Oregon Health and Science University /ID# 272282

    Portland, Oregon · Recruiting

  • University of Texas - Southwestern Medical Center /ID# 271914

    Dallas, Texas · Recruiting

  • Huntsman Cancer Institute /ID# 271618

    Salt Lake City, Utah · Recruiting

  • Northwest Medical Specialties Tacoma /ID# 272506

    Tacoma, Washington · Recruiting

  • Liverpool Hospital /ID# 272002

    Liverpool, New South Wales, Australia · Recruiting

  • Calvary Mater Newcastle /ID# 272498

    Waratah, New South Wales, Australia · Recruiting

  • St Vincent's Hospital - Melbourne /ID# 271997

    Fitzroy, Victoria, Australia · Recruiting

  • Epworth HealthCare /ID# 272497

    Richmond, Victoria, Australia · Recruiting

  • CHU de Liege /ID# 271430

    Liège, Belgium · Recruiting

  • UZ Gent /ID# 271432

    Ghent, Oost-Vlaanderen, Belgium · Recruiting

  • Universitair Ziekenhuis Leuven /ID# 272382

    Leuven, Vlaams-Brabant, Belgium · Recruiting

  • CHU de Montpellier - Hopital Saint Eloi /ID# 275570

    Montpellier, Herault, France · Recruiting

  • Hopital Universitaire Necker Enfants Malades /ID# 275571

    Paris, Île-de-France Region, France · Recruiting

  • Centre Hospitalier Universitaire de Poitiers /ID# 275563

    Poitiers, New Aquitaine, France · Recruiting

  • IUCT Oncopole /ID# 275568

    Toulouse, Occitanie, France · Recruiting

  • Centre Hospitalier Universitaire de Nantes, Hotel Dieu -HME /ID# 275562

    Nantes, Pays de la Loire Region, France · Recruiting

  • Universitaetsklinikum Hamburg-Eppendorf /ID# 275803

    Hamburg, Germany · Recruiting

  • Universitaetsklinikum Heidelberg /ID# 275598

    Heidelberg, Baden-Wurttemberg, Germany · Recruiting

  • Klinikum der Universitaet Muenchen Grosshadern /ID# 276658

    Munich, Bavaria, Germany · Recruiting

  • Universitaetsklinikum Wuerzburg /ID# 276657

    Würzburg, Bavaria, Germany · Recruiting

  • Rambam Health Care Campus- Haifa /ID# 271256

    Haifa, Israel · Recruiting

  • Hadassah Medical Center-Hebrew University /ID# 271253

    Jerusalem, Israel · Recruiting

  • Rabin Medical Center. /ID# 272073

    Petah Tikva, Central District, Israel · Recruiting

  • The Chaim Sheba Medical Center /ID# 271251

    Ramat Gan, Tel Aviv, Israel · Recruiting

  • Tel Aviv Sourasky Medical Center /ID# 271252

    Tel Aviv, Tel Aviv, Israel · Recruiting

  • Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico /ID# 276306

    Milan, Italy · Recruiting

  • The Jikei University Hospital /ID# 272091

    Tokyo, Japan · Recruiting

  • Nagoya City University Hospital /ID# 271427

    Nagoya, Aichi-ken, Japan · Recruiting

  • University Hospital Kyoto Prefectural University of Medicine /ID# 271911

    Kyoto, Kyoto, Japan · Recruiting

  • The University of Osaka Hospital /ID# 271636

    Suita-shi, Osaka, Japan · Recruiting

  • Japanese Red Cross Medical Center /ID# 272018

    Shibuya-ku, Tokyo, Japan · Recruiting

  • Uniwersytecki Szpital Kliniczny w Poznaniu - Szamarzewskiego /ID# 276237

    Poznan, Greater Poland Voivodeship, Poland · Recruiting

Showing 40 of 51 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.